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The Croatian Society of Medical Biochemists and Slovenian Association for Clinical Chemistry, together 
with the European Federation of Clinical Chemistry and Laboratory Medicine have organized 13th in a se-
ries of postgraduate weekend courses. These advance courses promote continuous postgraduate educa-
tion of professionals in clinical chemistry and laboratory medicine, and bring the participants up to date 
with different topics in laboratory medicine.
This time the course is entitled “New Trends in Diagnosis and Monitoring using Point of Care (POC) instru-
ments.” In this Course the state-of-the-art on Point of care testing (POCT) in different medical fields is pre-
sented and discussed by well-known experts. The lecturers will try to cover the clinical and laboratory as-
pects of POCT and discuss the advantage and shortcomings of this tool in different clinical settings. The 
integrated knowledge of the lecturers and the material prepared especially for this course intend to pro-
vide updated information of high quality to the participants. As always, most important in such courses 
are the interactions and discussions between lecturers and participants both during the course and in the 
free time.
We hope that for all those attending the Course it will be an excellent opportunity to acquire new knowl-
edge and exchange experience in the field.
Dubrovnik, October 2013
Elizabeta Topić & Sverre Sandberg
The thirteenth EFLM Continuous Postgraduate Course in Clinical Chemistry 
and Laboratory Medicine: New Trends in Diagnosis and Monitoring Using POC 
Instruments
Welcome note
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The role of POCT in modern medicine
Sverre Sandberg
The Norwegian Quality Improvement of Primary Care 
Laboratories (NOKLUS), University of Bergen, Bergen, Norway
Corresponding author: sverre.sandberg@isf.uib.no
Pont of care testing (POCT) is the most rapidly 
growing field in laboratory medicine. With increas-
ing technological and analytical possibilities, an 
increasing number of analyses can now be carried 
out on POC instruments. Although the costs of 
POC instruments are less than hospital instru-
ments, the number of users of POC instruments is 
much larger, ranging from wards in the hospitals, 
general practise (GP) offices, nursing homes, phar-
macies and last but not least tests for self-meas-
urements. With the increasing emphasis on patient 
empowerment, it is not surprising that POC instru-
ments can be an important factor in this, from self-
measurement of INR and glucose to a large and in-
creasing marked of “over-the counter” sold tests. 
The ultimate goal of using POC testing is that pa-
tient outcomes should be improved and/or that it 
should be more cost-effective than the use of con-
ventional laboratory testing. To achieve this, the 
role of POCT in the different clinical settings as 
well as the responsibility for introducing and man-
age the instruments and use of the instruments 
should be clearly defined. The main reason for us-
ing a POC instrument is that a rapid result is more 
useful than waiting for a result from a central labo-
ratory.
Whereas it is without doubt that the laboratory is 
responsible for analytical results when they are 
produced within “their walls”, it is not as obvious 
that the laboratory should have the responsibility 
for POC analyzing, and in many environments, this 
is not clearly defined. Therefore, the manufactur-
ers in many cases will communicate directly with 
nurses and clinical doctors when promoting their 
instruments rather than use their time with labora-
tory people and the idea is that no professional 
laboratory knowledge is necessary to handle these 
instruments. The laboratory specialists therefore 
must be more proactive and move out of the labo-
ratory and take responsibility for POC, even if it in-
volves difficult discussions with clinicians and hos-
pital managers. This way high quality POC can be 
ensured both for the pre-analytical, analytical and 
post-analytical phase and POC instrument can be 
a high quality service in modern medicine. In the 
present postgraduate course we will learn about 
POCT in different environments, hospital, GP offic-
es and patients as well as different measurements 
procedures that are introduced on POC equipment 
to be used in a variety of clinical settings. In the fu-
ture, there is probably no limitation to what tests 
can be performed on POC instruments, but the 
important task will be to define their usability (1).
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Hospital point of care testing network
Dunja Rogić
University Hospital Zagreb, Clinical Institute for Laboratory 
Diagnostics, Zagreb, Croatia
Corresponding author: drogic@kbc-zagreb.hr
Point of care testing (POCT) or near patient testing 
is defined as any in vitro diagnostic procedure 
done without the laboratory environment by non 
laboratory staff (1). Since it represents the fastest 
growing segment of in vitro laboratory diagnos-
tics worldwide, it clearly remains an ongoing chal-
lenge for laboratory professionals (2). By its nature, 
POCT falls within the interest and responsibility 
scope of the laboratory personnel, however by its 
location and means of use it belongs to other are-
as of patient care. Only the successful blending of 
these two determinant factors ensures adequate 
testing quality and results reliability. Within hospi-
tal environment (which represents about 70% of 
POCT market) it has become an indispensable part 
of any unit that requires immediate access to re-
sults, whether for medical or logistic reasons (4). It 
is of utter importance that laboratory staff remains 
 Biochemia Medica 2013;23(3):A62–A83 
 A65
Lecture abstracts
recognized and involved in decision making about 
hospital POCT at all stages. The optimal approach 
towards this goal is establishing a hospital POCT 
committee which should consist of all interested 
parties’ representatives: physicians who need the 
result, nurses who will do the testing, laboratory 
professionals who possess the required knowl-
edge about technologies and operating proce-
dures and last but not least, hospital administra-
tion who has to cover the costs. In terms of finan-
cial issues, it is highly advisable that cost coverage 
is clarified before any equipment is obtained – in 
other words, who will be covering the cost of 
equipment and/or consumables – generally this 
responsibility should not be taken by the labora-
tory but by the hospital department that needs 
POCT service (8). POCT instruments and equip-
ment should be carefully chosen only after the 
committee has reached a consensus regarding 
specific clinical needs and available means of ful-
filling them. The direct vending approach, where-
by IVD industry representatives offer their POCT 
product directly to clinical staff should be strongly 
discouraged or if possible explicitly forbidden. 
When a particular POCT equipment has been cho-
sen through the POCT committee, the laboratory 
should initially verify its performance and then or-
ganize education and training on site. If a parallel 
central laboratory procedure exists, the results 
comparability has to be checked and communi-
cated to the end users. Clinical staff needs to un-
derstand the possible consequences of inadequate 
sample handling, as well as main interferences 
possibilities and other existing constraints (9). User 
identification should be introduced as an indis-
pensable part of the training, since clinical staff 
has to stay aware of the fact that laboratory peo-
ple will be responsible for the functionality of the 
instrument, while they will be held accountable for 
each particular patient result. Regarding instru-
ment functionality, it can stay implemented usual-
ly mainly through continuous endeavours by labo-
ratory POCT dedicated staff to maintain the same 
quality standards applied within the central labo-
ratory – internal and external quality control, re-
mote review of test and instrument data, supervis-
ing the regularity of cleaning and maintenance 
procedures together with constant education and 
reeducation of clinical personnel. From this emerg-
es the last but far from least general rule of good 
POCT hospital service network, which is that ade-
quate and open communication between clinical 
and laboratory staff remains a conditio sine qua non.
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POCT in critical care units in the hospital
Robbert Slingerland
Isala Clinics, Department of Clinical Chemistry, Zwolle, The 
Netherlands
Corresponding author: R.J.Slingerland@isala.nl
The quality of point-of-care tests (POCT) within 
different segments and between different parts of 
the health-care chain is currently insufficiently 
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harmonized. Status of guidelines regarding the 
different segments of POC glucose measurements 
as one of the most profound used POC test will be 
presented.
Connecting all POCT instruments in and outside a 
hospital to central databases is an essential step in 
improving the continuity of data in the health-care 
chain. This lecture will address the involved 
necessary and standardized requirements from a 
laboratory point-of-view.
Patient’s privacy is at stake with increasing digital 
communication. The White House in the US has 
launched an initiative in 2010 to improve the pri-
vacy of patients and others in this market. The in-
creased use of Wi-Fi and other digital applications 
in and outside hospitals makes this initiative even 
more relevant. The clinical chemistry society needs 
to be more involved in solutions invented for tele-
com and finance market because these solutions 
will in the end or do already enter the medical 
POC-market. Currently, telemedicine based on re-
mote POCT is increasing rapidly. However, tele-
medicine can be a dangerous exercise if it is based 
on patient identification only. Patient authentica-
tion is an essential improvement for the near fu-
ture. An example how to perform safe digital au-
thentication with minimal patient credentials in-
volved will be presented.
This lecture will show some validation topics to 
ensure the quality of POCT in the hospital, which 
may be useable in the whole health care chain. 
The challenges in the critical care setting will be 
described regarding e.g. continuous glucose 
monitoring vs. point-to-point glucose comparison 
studies, statistic parameters involved and power 
of these statistic parameters.
Differences between glucose measurements in a 
hospital vs. home-use setting and consequences 
for the quality of the glucose measurement will be 
presented.
External quality control by POCT
Sverre Sandberg
The Norwegian Quality Improvement of Primary Care 
Laboratories (NOKLUS), University of Bergen, Bergen, Norway
Corresponding author: sverre.sandberg@isf.uib.no
External quality control or quality assurance (EQA) 
is in principle used to monitor the trueness of a 
measurement method and to compare results be-
tween measurement methods as well as to evalu-
ate the performance of a method in a single labo-
ratory (1). In principle every measurement method, 
be it in a central laboratory, outside the central 
laboratory as in emergency departments, operat-
ing theatres, clinical wards, general practise offices 
or pharmacies should participate in EQA. In most 
laboratories, it is usual that most if not all measure-
ments methods in the central laboratory partici-
pate in EQA. For measurements methods per-
formed outside the central laboratory – e.g. POC 
instruments, this is not always the case and there 
is a very different practice between countries/EQA 
organizations as exemplified with the presence – 
or not presence of EQA schemes for INR (2). One of 
the reasons for this are the difficulties in finding 
adequate quality control materials for different 
measurements methods and also the opinion by 
some that EQA is not necessary for POC instru-
ments. The most important problem with the con-
trol material is that it should be commutable be-
tween methods, patient like, stable and homoge-
neous. For POC methods, this can be especially 
challenging since many of them uses capillary or 
whole blood for their measurements and the 
number of POC instruments can be very large. The 
challenge of not having a commutable control ma-
terial for POC instruments can be circumvented by 
the estimation of trueness of the measurement 
method and participant performance separately 
and the feedback report summarizes these results 
(3). The worst case is when the use of “poor” con-
trol material, introduce “errors” that are not present 
when patient-like material is used (4). EQA of POC 
instruments should also involve pre(pre)- and 
post(post)-analytical aspects. For POC instruments, 
this will probably be even more important than for 
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the central laboratory since the users usually have 
little formal laboratory education. It is therefore a 
challenge to set up EQA schemes for these phases. 
Since such schemes do not need control material, 
it is usual to circulate them only in a paper forms 
or as an electronic questionnaire/registration. This 
is done by e.g. KIMMS in Australia, but not for POC 
instruments (5). Post-analytical surveys of the in-
terpretation and use of POC instruments have 
been carried out as surveys among European 
countries(6). Even if EQA might be difficult, EQA of 
self-measurements might be even more challeng-
ing and alternative ways of doing this should be 
explored.
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QC net in hospital’s POCT
Marija Prezelj
Institute of Clinical Chemistry and Biochemistry, University 
Medical Centre Ljubljana, Ljubljana, Slovenia
Corresponding author: marija.prezelj@kclj.si
Two decades ago, there was practically no elec-
tronic data management for POCT. All information, 
including tests results, material handling data, and 
result reporting comments, had to be manually 
entered into the patient chart, tables, and log-
books located on the patient care units. Docu-
menting all this data is not only time consuming 
but also prone to errors, and extra care must be 
taken in verifying the entry of these data. Real-
time data management and review POCT data was 
not possible. There also were no guidelines in 
place to ensure that all POCT devices were de-
signed in a manner to be interfaced to electronic 
data management systems. The goal of CIC (Con-
nectivity Industry Consortium), formed in 2000, 
was to develop standards for connectivity of POCT 
devices to permit bidirectional vendor-independ-
ent connectivity. Connectivity requirements have 
been described in the Clinical and Laboratory 
Standards Institute (CLSI) POCT Connectivity Ap-
proved Standard (POCT1-A2) and in the CLSI pro-
posed guideline POCT2-P (POCT Connectivity for 
Healthcare Providers).
POCT connectivity devices [definition - devices with 
the ability to link point-of-care devices to each oth-
er, to laboratory information systems (LIS), or both 
(CLSI)] with a built in bar code reader is used to iden-
tify the test strips, for quality controls and to record 
the identification of the patient and operator. The 
device will not operate unless quality control has 
been performed. Quality control rules are built into 
the device software to ensure that patient testing 
cannot be performed unless the instrument is in 
control. Despite high level of technological sophisti-
cation in POCT devices today, the role of traditional 
quality control and external quality control re-
mains significant confirmation for reliability of 
tests results. Quality control sample must be ana-
lyzed at a frequency recommended by the manu-
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facturer and should be performed periodically as 
proposed in national guidelines for POCT. External 
quality control is desirable and required for POCT 
devices as stated in the international standard, ISO 
22870 “Point–of-care testing (POCT) – requirements 
for quality and competence”.
Quality control is immediate check on integrity of 
the POCT device and therefore the operator should 
record the result and take appropriate action in 
the time of testing. However, the POCT operation-
al team of each unit should review the day-to day 
operation of POCT, the quality control and exter-
nal quality control results.
Supervision of quality control measurements 
should be performed by the central lab, the best 
way is on the online connection of all POCT sys-
tems to the central lab via LIS/HIS network.
Institute of Clinical Chemistry and Biochemistry at-
tempts the implementation of bidirectional HIS 
network of POCT devices in the Intensive Care 
Units of Internal and Paediatrics Division with two 
POCT servers and with LIS linkage.
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Quality indicators of POCT
Ivana Baršić
Department of Laboratory Diagnostics, University Hospital 
Centre Zagreb, Croatia
Corresponding author: ivbarsic@yahoo.com
Point-of-care testing (POCT) or near-patient test-
ing is performed near or at the site of a patient, 
with test results leading to a possible change in 
the care of a patient. These tests are performed 
outside the central hospital laboratory. Neverthe-
less, POCT main principles do not differ significant-
ly from those governing the central hospital labo-
ratory. We want to get the right test for the right 
patient, getting the right specimen and the right 
results in the right time, getting the right patient 
record and timely the right treatment. Therefore, 
we need to ensure good quality control and pa-
tient safety.
One way is to establish good quality management 
system and to develop quality indicators. As in the 
central hospital laboratory, it is preferable and im-
portant that indicators include all three phases in 
the working process: preanalytical, analytical and 
postanalytical. Quality indicators need to be de-
signed to monitor processes that have the poten-
tial to put patients in risk so they should include a 
focus on patient safety and clinical effectiveness.
Quality indicators need to be clearly measurable 
so we need to establish what do we want to meas-
ure, can we get these information, how to analyze 
the obtained data, how often it will be done, etc.
There are still no clearly defined quality indicators 
for POCT so that each laboratory responsible for 
the organization and management of POCT should 
define its own.
Here are some POCT quality indicators: number of 
bad quality samples, number of wrong samples, 
samples without identification (no patient identifi-
cation), sample handling errors (number of inade-
quate sample – haemolytic, clotted, insufficient 
sample volume, inappropriate collection contain-
er, etc.), education documentation (certification), 
critical values notifications, quality control per-
formance (internal and external quality control), 
instrument management (instrument evaluation 
and validation, calibration verification, method 
correlation, instrument maintenance), inventory 
management (reagents and controls), incident re-
ports, reporting patient results, number of missing 
patient results records, number of cases where op-
erator didn’t detect interference, reporting inci-
dents, etc.
Ultimate goal is to ensure patient safety and opti-
mal care. Finally, it is of great importance to ensure 
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good communication between the central hospi-
tal laboratory and staff performing POCT (non-
laboratory staff). However, communication cannot 
be measured. Knowing that poor communication 
is a source of many mistakes, POCT requires its in-
clusion as an “immeasurable indicator” that will 
significantly improve the quality of POCT.
Maintaining high quality standards in POCT con-
tinuously proves to be a growing challenge for 
laboratory professionals.
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POCT in celiac diseases
Jernej Dolinšek
Department of Paediatrics, Gastroenterology Unit, University 
Medical Centre Maribor, Maribor, Slovenia
Corresponding author: jernej_dolinsek@hotmail.com
Celiac disease (CD) is a systemic immune disorder 
triggered by the ingestion of gluten, a protein 
present in wheat, rye and barley in genetically pre-
disposed individuals. The prevalence of CD in vari-
ous populations around developed world is 
around 1%; however, the disease is largely under-
estimated in many regions. There is also evidence 
that diagnostic delays can reach more than a dec-
ade, especially in adult patients, which can have a 
major impact on their well being, and general 
health of population. Evidence also exists to show 
that the prevalence of the disease increases with 
the age, being more prevalent in adults and elder-
ly than in children, which is in the contrast with 
previous belief that celiac disease is rather rare dis-
ease affecting only children.
Celiac disease can manifest itself at any age. It may 
be clinically silent; some patients may show only 
vague symptoms or present with extra intestinal 
manifestations. This also can influence the diag-
nostic approach and can yield to late diagnosis of 
the disease.
It is well known that celiac disease runs within fam-
ilies, and first-degree relatives of patients are at 
much higher risk of developing the disorder. It also 
holds true for other risk groups such as patients 
with type 1 diabetes, IgA deficiency, autoimmune 
thyroiditis, as well as patients with Down, Turner 
and Williams syndrome.
Even if health care professionals are highly aware 
of all the above-mentioned facts, active approach 
in patient finding is not common. General screen-
ing with classic serological tests including antibod-
ies against tissue-transglutaminase type 2 (t-TG), 
deamidated gliadin peptide antibodies (dGP) and 
antiendomysium antibodies (EMA) is not recom-
mended by current guidelines adopted by Euro-
pean Society for Pediatric Gastroenterology, Hepa-
tology and Nutrition (ESPGHAN).
Active case finding in primary care using sensitive 
and specific biomarkers of celiac disease might be 
a solution to shorten diagnostic delays. However, 
using classic serological tests in centralized labora-
tories are not available or affordable for medical 
health care in many parts of the world.
Easy-to-use whole blood self-TG2-based fingertip 
point-of-care test (POCT) as well as rapid tests 
based on the detection of dGP antibodies have 
been developed and were proven in several set-
tings to be effective in celiac disease case finding. 
These tests are qualitative tests, do not need so-
phisticated equipment, and can be interpreted by 
unskilled personnel.
POCT tests for celiac disease proved to be highly 
sensitive and specific resulting in an accuracy of 
>95% to detect untreated CD reported by some au-
thors. Their use can be somewhat limited in patients 
consuming gluten free diet, who must be checked 
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regularly for possible dietary violations, which limits 
their home use. Possible misinterpretations can 
yield to over- or underestimation of the disease.
A better, quantitative POCT test that could simul-
taneously detect disease specific antibodies and 
level of total IgA as well as determine HLA status 
of patients within a visit time, and could communi-
cate with Laboratory information system has been 
developed within the CD-MEDICS project and 
needs further validation, but has already shown 
some initial promising results.
POCT coagulation
Steve Kitchen
UK National External Quality Assessment Scheme (UK NEQAS) 
for Blood Coagulation
Corresponding author: Steve.kitchen@sth.nhs.uk
POCT in haemostasis and thrombosis is increas-
ingly used in many countries. The main applica-
tions are currently as follows: INR for monitoring 
vitamin K antagonist therapy by healthcare profes-
sionals and patient self testing; high dose heparin 
management using activated clotting time (ACT); 
assessment of global haemostasis using throm-
boelastometry (ROTEM) or thromboelkastography 
(TEG); D-dimer testing for exclusion of venous 
thromboembolism (VTS); platelet function testing 
including assessment of anti platelet therapy.
Both internal quality control (IQC) and, where 
available, external quality assessment (EQA) are re-
quired to provide the evidence that results are safe 
for use in patient management decisions. A 
number of different POC INR monitors are availa-
ble, some of which incorporate some form of in-
built IQC. There are advantages to having access 
to IQC materials which mimic patient samples and 
which can be analysed in a similar way to patient 
samples, thereby testing the full analytical process 
including any test strips or cartridges and the func-
tioning of the monitor. IQC can provide important 
evidence related to the precision and consistency 
of testing and to ensure that results are in agree-
ment with those obtained in other centres.
UK NEQAS (blood coagulation) currently offers pro-
ficiency testing programmes for the following POC 
tests and devices: INR – Roche Coaguchek XS/XS/XS 
PRO; Haemochron junior signature series: INR Ab-
bott – ISTAT: ROTEM: TEG: ACT-Haemochron series.
The most commonly used INR monitor amongst 
UK NEQAS participants are the Coaguchek XS and 
XS plus devices. A lyophilized anti-coagulated 
sample prepared from plasma obtained from pa-
tients treated with warfarin is provided together 
with reconstitution and decalcification solutions 
so that no local pipettes, diluents or laboratory fa-
cilities are required for analysis.
ROTEM (INTEM and EXTEM tests) and TEG results of 
a NEQAS survey in which a pooled normal plasma 
sample was used as test material are shown below:







Rtime (min) 6.3 27 5.2–14.1
Angle (degrees) 76.2 9 54.8–79.8
K time (min) 0.9 52 (9)* 0.8–3.8
MA at 20 min 42 11 39.6–69
* Figure in brackets is the CV after removal of outliers > 5 SD 
from median.







CT (sec) 149 12.6 135–196
Angle (degrees) 84 1.2 81–85
CFT (sec) 28 16.4 24–43
MCF (mm) 38.5 9.4 30–46







CT (sec) 435 131 (29)* 35–417
Angle (degrees) 85 7 (1)* 12–87
CFT (sec) 26 91/18 19–147
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MCF (mm) 41 8 38–50
* Figure in brackets is the CV after removal of outliers >5 SD 
from median.
Results obtained in 12 months of ULK NEQAS sur-
veys for the CUC XS plus the most commonly used 
device are shown below.
Sample N Median INR Range CV%
XS12:03 2165 2.00 1.00–7.10 14.1 (18.3)*
XS12:04 2166 3.60 1.90–8.00 10.3 (13.9)*
XS12:05 2250 3.40 2.00–8.00 9.3 (14.0)*
XS12:06 2245 4.10 2.10–8.00 11.1 (14.7)*
XS12:07 2246 3.30 2.10–8.00 10.1 (14.5)*
XS12:08 2242 4.30 2.40–8.00 7.3 (10.0)*
XS13:01 2384 3.50 1.50–8.00 9.0 (15.5)*
XS13:02 2382 3.90 2.10–8.11 8.2 (12.8)*
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Arterial blood gases (ABG’s) is a collective term ap-
plied to three separate measurements pH, pCO2, 
pO2 generally made together to evaluate acid-
base status, ventilation, and arterial oxygenation. 
With the arrival of more recent ABG’s analyzers 
and the evolution of the concept of point of care 
testing (POCT), what we meant for BG analysis has 
been redefined and extended also to meet the 
needs of critical care and emergency medicine, 
particularly in managing traumatic and septic pa-
tient (1,2). In particular, alongside the traditionally 
measured parameters, the cations (sodium, potas-
sium, calcium and chlorine) and lactate were add-
ed. This allowed us to address more detailed issue 
related to the acid-base disorders and those relat-
ed to electrolyte disorders. In the field of oxygena-
tion same measured parameters have been intro-
duced such as haemoglobin and his fractions 
(FO2Hb, FHHb, FCOHb, FMetHb) and saturation of 
haemoglobin with oxygen (SaO2). This allowed 
rapidly discovering some intoxications (e.g. CO and 
nitrate). Now it is possible to use POCT specific 
software to help physicians in interpreting the 
ABG’s complex disorders.
In recent years point-of-care testing ABG’s analyz-
ers have been increasingly used in the emergency 
department (ED) because there are times when 
emergency physicians (EPs) need to have test re-
sults readily available. The decision-making proc-
ess in the ED begins with the main complaint ex-
pressed by the patient at triage and then proceeds 
with the differential diagnosis, risk stratification 
and early therapy, when necessary. The process 
ends with the patient admission or discharge.
Within each of the critical nodal points of this deci-
sion-making process, the physician may need to 
receive the results of some tests as quickly as pos-
sible in order to make a prompt diagnosis, define 
risk stratification and establish an early therapy or 
change it.
What EPs need in the ED is a rapid turnaround time 
(TAT) or a quite as rapid turnaround time therapy 
(TATT). The effectiveness of ABG’S POCT in the 
management of critical patients has been proved 
by a randomized controlled trial and many other 
studies have been conducted to assess the useful-
ness of POCT in the ED, whose availability, fortu-
nately, continue to rise, contributing to improve 
patient quality of care and outcome (3,4).
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Timeliness in diagnosis and therapy represents an 
essential requirement in the care of patient with 
chest pain. Cardiac troponins (both troponin I and 
T, cTn) are the preferred biomarkers for diagnosis 
of myocardial infarction (MI). Point-of-care (POC) 
methods can provide cTn results more rapidly than 
alternative methods, potentially accelerating 
triage, acute myocardial infarction diagnosis, and 
improved outcomes. In principle, quality specifica-
tions (imprecision, bias and analytical sensitivity) 
for cTn POCT should be the same as those for cen-
tralized laboratory assays. However, currently avail-
able POC assays may be less sensitive compared to 
centralized laboratory assays, namely when com-
pared to the current generation of assays, usually 
called “high-sensitivity troponin assays” (1). Some 
papers, in fact, documented the misclassification 
rate of patients when cTn is measured with poor 
analytical sensitivity assays. Therefore, (POC) meth-
ods represent a viable option for cardiac troponin 
assay when clinical laboratories: a) cannot deliver 
results in the time consensually defined with clini-
cians (usually, within 60 minutes from blood sam-
pling); b) when a 24 hour service is not available 
(laboratory closed at nights and/or week-ends); c) 
are poorly connected with wards both for sample 
transportation and results communication by lab-
oratory/hospital information systems; d) when pa-
tients are attended in settings lacking alternative, 
more sensitive methodologies as those existing in 
rural, remote sites; and e) if the cost/benefit analy-
sis confirms the value of this option. In addition, it 
should be emphasized that current recommenda-
tions for MI diagnosis stress the need to obtain se-
rial samples for cTn measurement, namely at the 
presentation (baseline) and after 3 and 6 hours (2). 
Therefore, both rule-in and rule-out strategies can-
not be based on only one blood sample. As results 
from different assay methods are not interchange-
able, for an institution having both POC and cen-
tral laboratory methods for cTn measurement, it is 
advisable to use the same analytical method for 
tracking serial results on any individual patient. 
Therefore, although timeliness is an essential re-
quirement for cTn assays, an important factor in 
determining its clinical utility is the diagnostic per-
formance which, in turn, is related to the analytical 
sensitivity, reproducibility and accuracy. As there is 
a lack of standardization and harmonization in the 
measurement for all cTn assays, each laboratory 
needs to understand the strengths and weakness-
es of assays they implement into clinical practice, 
including POC, with the understanding that differ-
ent assays often give different clinical results. The 
measurement and monitoring of the “vein-to-vein” 
turnaround time (TAT) is a critical quality indicators 
for cTn assay, but the adoption of a valuable cut-
off and an appropriate imprecision value (CV < 
10%) at that cut-off are fundamental issues for as-
suring quality and patient safety in the manage-
ment of chest pain patients.
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POCT is one of the fastest growing aspects of clini-
cal laboratory testing, with estimated increase of 
at least 10-12% for year overall and to 30% per year 
in some testing areas. In the area of drugs of abuse 
(DOA) alone POCT represents a multimillion Euros 
business. Generally, such testing relies on urine as 
the sample and targets the more commonly 
abused substances and/or their metabolites. Infor-
mation obtained in such a way can be used in dif-
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ferent clinical and non-clinical settings, among 
them some very specific, like visiting nurses, trans-
port vehicles (ambulances), prisons, army etc. 
POCT devices for DOA are available in different for-
mats, from dipsticks, cards and plastics cassettes 
or cup devices. A small amount of urine is needed 
to perform the test and only 3 drops of urine, or 
approximately 150 μL, is a usual testing volume. 
Cups are intended as a collection/container device 
for urine as well. Turnaround times from initial 
sample application to a result are 15 min or less. 
Currently, all devices are based on immunoassay 
principle and final result is read visually and de-
pends upon technological approach. Majority of 
POCT products in this testing area represents a lat-
eral flow based immunoassay system. The techni-
cal basis was derived from the latex agglutination 
assay, RIA and ELISA, supported with several major 
patents on this technology. The first lateral flow 
products were introduced to the market in the late 
1980s. Unlike other qualitative POCT devices, most 
devices for DOA testing give a negative visual sign 
when the drug of interest is positive. There is some 
confusion among users, because devices for differ-
ent POCT application use almost the same design 
of device housing.
Regarding the intention of use, specific drug or 
drug group can be the target molecule. When the 
parent drug is extensively metabolized, the drug 
metabolite is the preferred target. There is no abso-
lute concordance with comparator method and the 
highest disagreement can be seen for samples close 
to a cut-off value. It is generally accepted that POCT 
device sensitivity is the main test characteristic ena-
bling the test use in specific circumstances.
It needs to be noted that users of POCT for DOA 
should be aware of the cross-reactivity to related 
drugs and possible adulteration of urine sample. 
The cross-reactivity may arise from food, pre-
scribed drug, or other sources. However, samples 
could also be tampered with added substance, 
knowing to change the composition of urine, pro-
ducing negative test result. Sometimes, weakness 
in specificity of the test can be used in screening 
purpose, searching a group of drugs, changed re-
garding the drug origin. Recently, great effort is 
placed into research for POCT device detecting the 
new synthetic products in group of cannabinoids 
and synthetic amphetamine-like drugs.
POCT is a highly dynamic discipline. With the evo-
lution of technology, the spectrum of POCT for 
DOA is expected to change over time. The users of 
POCT for DAU should follow guidelines for POCT, 
using quality control material and participate in 
external quality assurance schemes.
POCT in diagnosing and monitoring of 
diabetes mellitus
Sverre Sandberg
The Norwegian Quality Improvement of Primary 
Care Laboratories (NOKLUS), University of Bergen, Bergen, 
Norway
Corresponding author: sverre.sandberg@isf.uib.no
POC HbA1c is commonly used for monitoring of 
diabetes mellitus. In a monitoring situation more 
emphasis is usually placed on precision and less 
on trueness. Concerning HbA1c, however, one can 
argue that the same quality specifications should 
be used both for monitoring and diagnosing since 
many of the recommendations for good practice 
deal with absolute HbA1c numbers and not only 
“improvement” or “deterioration” of the diabetic 
condition. An expert committee officially recom-
mended to use HbA1c for the diagnosis of diabe-
tes in 2009 (1). There are several advantages of us-
ing HbA1c compared with glucose such as pre-an-
alytical stability of the sample and low within-sub-
ject biological variation of HbA1c (1). Furthermore, 
HbA1c is stable throughout the day and fasting 
and dietary restrictions are therefore avoided. 
World Health Organization (WHO) recommends an 
HbA1c level of 6.5% (48 mmol/mol) as the cut off 
point for diabetes, and the assays must be “stand-
ardized to criteria aligned to the international ref-
erence values” (2). The College of American Pathol-
ogist (CAP) recommends that the EQA acceptable 
limits for accuracy should be 7% in 2012 and 6% in 
2013 compared to a target value (6). Furthermore, 
NACB recommends a within-laboratory CV < 2% 
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and a single method should have a between-labo-
ratory CV < 3% (3). All CVs are based on the DCCT 
(Diabetes Control and Complications Trial)/NGSP 
units (3). NACB recommends using hospital labora-
tory HbA1c instruments for diagnosis of diabetes 
since POC HbA1C assays are “currently not suffi-
ciently accurate for this purpose” (3). Results using 
Afinion and DCA instruments in the hands of trained 
personal have shown that these instruments have 
the potential to fulfil the above mentioned quality 
specifications (4,5). These studies, however, were 
laboratory experiments following the CLSI EP-5 
guidelines and not longitudinal results from clinical 
practice. In a recent study (6) results from 13 HbA1c 
external quality assurance surveys (EQAS) during six 
years in from both GPs offices using POC instru-
ments and from hospital laboratory instruments 
were compared with the recommended analytical 
quality specifications for using HbA1c diagnosti-
cally for diabetes mellitus. All general practice and 
hospital laboratories measuring HbA1c in Norway 
participated in the EQAS. Between 60-90% of Afin-
ion and DCA users and hospital laboratories per-
formed HbA1c measurements within the quality 
specifications for both trueness (6.0%) and impreci-
sion (CV ≤ 2.0%) in two levels in each EQA survey.
In conclusion, results indicate that Afinion and 
DCA POC instruments for measurements of HbA1c 
can fulfil the analytical quality specifications for di-
agnosing diabetes mellitus, and have an analytical 
quality comparable to hospital laboratory instru-
ments. A presupposition for using these instru-
ments for diagnosing diabetes mellitus is that a 
stringent quality assurance program is established 
to monitor the quality.
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A steep increase in the number of type 2 diabetics 
and other chronic diseases world-wide is observed 
(1). Health care is getting yet an overstretched sys-
tem. Choices will have to be made considering the 
kind of care that will be provided. What are the 
pushes in this process? What is the role of POCT in 
this respect? Who is in charge in this process?
Although the glucose meters used by patients may 
well be of good quality for patients in general, in-
terfering substances in the patient’s blood may in-
fringe on the measurement technique of the pa-
tient meter issued (2). Due to this, glucose meas-
urement interfering substances may lead to incor-
rect glucose values and may result in undertreat-
ment or overtreatment of diabetics, with risk of di-
abetes associated pathology.
What quality of POC testing is needed from this 
perspective? Concomitantly with the increase in 
the number of diabetics the number of inaccurate 
blood-glucose measurements will also increase, 
resulting in a decrease in quality of life due to in-
creased diabetes associated pathology and conse-
quently causes an increasing burden on the 
health-care costs.
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Can we achieve the same quality for POC/home-
use/lab instruments in the entire health care sys-
tem? Is this essential? What criteria are relevant? 
What flow-diagram is optimal in checking the 
quality of home-use glucose instruments in pa-
tients hands and why? What are trends for POC/
home-use testing?
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According to a recently published article in New 
England Journal of Medicine “traditional testing is 
usually performed in remote laboratories which 
increases the cost and inconvenience of accessing 
health care and leads to a high number of patients 
who leave the system before a diagnosis is estab-
lished” (1). Rapid point-of-care testing (POCT) have 
been advocated to improve accessibility to health 
care services and timeliness in diagnostic and ther-
apeutic pathways. In fact, POCT devices for blood 
gas analysis, electrolytes, glucose, and many other 
tests have long been available and have become 
common diagnostic tools. New generations of 
POCT detect more complex and less accessible bi-
omarkers, such as nucleic acids and cell-surface 
markers taking advantage of advances in microflu-
idics, microelectronics, optical systems and infor-
matics. However, in spite of major improvements 
in technology, assuring the quality of POCT re-
mains challenging (2). In addition, most studies 
have evaluated the analytical performances of 
POCT devices without taking into consideration 
pre- and post-analytical issues. However, accord-
ing to a total quality and patient-centred scenario, 
there is the need to adopt a framework that allows 
the evaluation of quality in all steps of the process, 
as proposed by Kost several years ago.
In the pre-analytical phase major problems arise 
from: a) patient misidentification/incorrect pa-
tient’s details; b)test order not documented; c) 
wrong tube/anticoagulant; d) in vitro haemolysis; 
e) clotting, f) wrong storage condition. For exam-
ple, in blood gas analysis, major errors document-
ed in the pre-analytical phase are related to: pa-
tient and sample identification, patient stabiliza-
tion, choice and preparation of the collection site, 
collection device(s), type of anticoagulant, sample 
treatment after collection, and sample transporta-
tion. In the post-analytical phase major problems 
are related to a) transcription errors (3), b) meas-
urement units and reference ranges; c) lack of doc-
umentation; and d) wrong results interpretation.
Connectivity and bidirectional interface with the 
laboratory information systems represent an indis-
pensable requirement for minimizing the risk of 
errors and the lack of documentation as there is 
the need to include POCT results in the patient 
electronic record. This makes more intriguing the 
search for harmonizing units of measure, reference 
ranges and target values. Therefore, despite major 
advances in device design and informatics, the 
management of a successful POCT program re-
mains very challenging.
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Evaluation and selecting of POCT devices
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The use of point of care devices (POCT) methods 
varies greatly among different health care settings. 
For some regions, the use of POCT is controlled 
through guidelines for its use, or through system 
for compensating for the cost of use. In Sweden, 
the use of POCT varies much according to a recent 
survey, and the variation is not related to e.g. close-
ness to central laboratory facilities. The frequency 
of use is probably very much determined by inter-
est shown by local doctors.
The selection process for a POCT device should lie 
in the hands of a management group, securing 
that different aspects of use of POCT are covered. 
The purpose for using POCT should always be con-
sidered: Should the POCT measurement improve 
the decision making in a specific area, e.g. reduce 
the prescription of antibiotics, or simplify the lo-
gistics, e.g. reducing the number of visits or tele-
phone calls for patients, or should it improve the 
patients confidence, e.g. for patients also using de-
vices for self monitoring.
Point of care methods must be as accurate as „cen-
tral laboratory methods“ in order to be reliable. 
Even if proven accurate in a once performed eval-
uation, the POCT method in use must continuous-
ly be controlled for accuracy through the partici-
pation in a system for EQA, just as central labora-
tory methods are controlled. Compared to labora-
tory methods for measurement in venous plasma, 
it is an extra challenge for the EQA organizers to 
provide commutable EQA material for the use of 
POCT devices, made for measurement of capillary 
whole blood.
The Scandinavian evaluation of laboratory equip-
ment for primary health care (SKUP) project has 
until now evaluated more than 100 different de-
vices. The evaluations are ordered by the producer 
of the device or its local distributer, who also cov-
ers a part of the cost for the evaluation. For devices 
on the Scandinavian market, the results of the eval-
uation are published regardless of the outcome. 
The reports are freely available at www.skup.nu.
The evaluation of accuracy should ideally be done 
against primary or secondary reference methods. 
However, this is almost never possible, but the se-
lected comparison method must be controlled. 
The comparison method should not be selected 
to suit the evaluated method.
The accuracy of results found in the evaluation is 
an important outcome of the evaluation. However, 
the user friendliness, rated by the evaluators, 
might also be an important variable to consider 
when a POCT device is selected. Some POCT de-
vices need specially educated and trained staff for 
maintenance. The connectivity is important. The 
device should be able to communicate with the 
health care record system. This simplifies the proc-
ess of transferring the results to the patient’s med-
ical record.
The cost of the device and its consumables is just 
one of several variables to consider in the selec-
tion process. The cost for staff and maintenance 
should also be considered when comparing cost 
between different alternatives. In an ideal world, 
results from all instruments, POCT and non-POCT, 
used in a region should be aligned and share the 
same reference range.
Evidence has been shown for improved primary 
health care by the introduction of POCT tests for 
Glucose, Haemoglobin, HbA1c, CRP and (PT) INR. 
On the other hand the use of POCT tests for Tro-
ponin has been questioned, because of the lower 
accuracy for the Troponin POCT methods compared 
to the current central hospital laboratory methods.
Benefits and disadvantages of POCT
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Point of care testing (POCT) has been used for 
many years to control diabetic patients either at 
clinical/general practice settings or as self-control. 
Blood glucose was the first test analyzed by POC 
instruments. The number of POC analyses contin-
uously increased and slowly developed into pow-
erful tools to use in management of a number of 
common diseases such as diabetes, hyperlipi-
demia, cardiovascular disease or impairment need-
ed anticoagulant therapy (1,2).
POCT is defined as any test that is performed at 
the time at which the test result enables a clinical 
decision to be made and an action taken that leads 
to an improved health outcome. It may be useful 
adjunct in the management of patients with 
chronic disease or in emergency.
After a long time of POC instruments on the mar-
ket many questions related to POCT appeared re-
garding the analytical performance, clinical effec-
tiveness, costs, satisfaction of the patients and 
health care professionals both clinicians or labora-
tory professionals.
Related to analytical performance, the minimum 
requirement for analytical reliability are precise-
ness, accuracy and range of measurements. So far, 
there are many producers of POC instruments on 
the market, each of them declares satisfactory 
characteristics; however, the consumer should be 
very careful in selecting it because many discrep-
ancies related to the above mentioned character-
istics can be found in the literature.
Related to the clinical effectiveness there are not 
so many reports in the literature on satisfaction of 
health care professionals with POC testing or POC 
instruments. There are only few articles related to 
the clinical outcomes, suggesting more rational-
ized treatment, but changes in prescribing pat-
terns have not occurred or they occur very seldom. 
Some evidence is available on the role of POCT in 
improving glycaemia, cholesterol and lipid levels 
and oral anticoagulant control.
For laboratory professional, it is important that the 
POCT introduced in certain environment is proven 
to be accurate and reliable to meet internal quality 
control and external quality assurance standards. 
The model for POCT in primary care that incorpo-
rates laboratory training for GP staff with external 
QA from the central laboratory is suggested. An 
essentially part of quality management is the ade-
quate training of staff operating the POC instru-
ments including the requirement for understand-
ing of QC and QA processes.
Satisfaction of patients: In the example for acute 
cough/LRTI, patients were satisfied with quick test 
results of CRP using POCT what enabled physicians 
to make an immediate decision about antibiotic 
therapy. The most common advantage discussed 
by patients was that POCT is a useful diagnostic 
tool that gives the clinicians more information to 
make better decisions about the treatment, which 
is then administered more quickly, resulting in 
faster recovery of patients. There are some other 
reports on satisfaction of patients by POCT (3,4).
Costs effectiveness may be considered from sev-
eral different aspects, as POCT versus laboratory 
testing, number of patient visits to physicians, bet-
ter control, less medication, faster medical deci-
sion making and so on.
In the presentation satisfaction of POC instrument 
producer, laboratory users, satisfaction of physi-
cian and of patients and on cost effectiveness us-
ing the POC instruments will be discussed.
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Introduction: Point-of-care (POC) devices such as 
the Accutrend® Plus are helpful in the measure-
ment of lipid levels and have been validated in the 
laboratory setting, but not in a busy general prac-
titioners office. Since the Accutrend® Plus device 
has recently been recommended as an additional 
tool in the personal management of dyslipidemi-
as, it’s of the utmost importance to ensure that the 
precision and accuracy of this POC device is satis-
factory.
Materials and methods: The sample consisted of 
61 randomly chosen individuals (≥ 18 years) with-
out known history of cardiovascular disease 
events. Simultaneous capillary and venous blood 
testing was undertaken on the Accutrend® Plus 
handheld lipid analyzer and a reference instru-
ment (Vitros® 5.1 FSchemistry system) respectively. 
To stimulate a true picture of the usual clinical set-
ting all blood samples were taken in the private of-
fice of each subject’s general practitioner after a 
fasting period of at least eight hours.
Results: The results show that the Accutrend® Plus 
system provided significantly lower values (P < 0.01) 
of total cholesterol (TC) but not of triglycerides (TG) 
(P > 0.05) as compared to the values determined in 
the laboratory. The agreement between methods 
fell outside clinically acceptable limits for blood lip-
id measurement (TC ≤ 8.9%, TG ≤ 15%), as stated by 
NCEP recommendations. However, a good be-
tween-day reproducibility (ICC: TC = 0.85, TG = 0.68, 
P< 0.001) and significant concordance (P < 0.001) 
with the laboratory method was found.
Conclusion: Accutrend® Plus lacks precision and 
accuracy compared to a reference chemistry sys-
tem. However, its reproducibility also suggests 
that this portable POC device might be useful for 
the monitoring of metabolic disorders and cardio-
vascular risk factors. Clinicians should be aware 
that fluctuations of 0.75 mmol/L (29 mg/dL) for TC 
and 0.88 mmol/L (78 mg/dL) for TG are to be con-
sidered as non-significant under constant diet cir-
cumstances.
Key words: reproducibility of results; cholesterol; 
triglycerides
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Inter-lot variation with C-reactive protein 
(CRP) point of care testing (POCT): The 
need for external quality assessment .
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*Corresponding author: a.albersen@shl-groep.nl
Background: Dutch GP’s use the CRP value to help 
differentiate mild lower respiratory tract infection 
from pneumonia in moderately sick adults. In the 
latter antibiotics will be prescribed as mentioned 
by the Dutch practice guideline “acute cough” 
which advocates the use of CRP-POCT in a primary 
care setting. Our laboratory provides eighty GP’s 
with CRP-POCT. Recently, discrepancies were 
found between the CRP-POCT and our laboratory 
assay with monthly internal quality controls (IQC) 
with patient serum. This was not observed in the 
weekly IQC with control levels from the manufac-
turer.
Materials and methods: The CRP-POCT (Afinion 
AS 100), with two different lot-numbers, was com-
pared with the Unicel (Beckman-Coulter) and Co-
bas (Roche Diagnostics) CRP assay using patient 
sera. Furthermore, retrospective data analyses of 
IQC results with patient material was performed.
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Results: The CRP-POCT results show a positive 
bias compared to both the Unicel- and Cobas as-
says. Passing-Bablok regression analyses gave the 
following results: Afinion = 1.30 x Cobas - 3.01; 
Afinion = 1.10 x Cobas + 0.75; Afinion = 1.22 x Uni-
cel - 2.64 and Afinion = 1.02 x Unicel + 1.81 with lot 
number 1 and 2, respectively. Data analyses show 
a positive shift in our IQC results in the last quarter 
of 2012 when compared to an earlier period.
Conclusions: Our CRP-POCT showed a lot-de-
pendent positive bias compared to the Unicel- and 
Cobas assay which can be up to 20% and could 
lead to unjust use of antibiotics. The IQC serum re-
sults shift was attributable to a recalibration of the 
Afinion CRP-reagents by the manufacturer. Above 
results justify external quality assessment for POCT 
devices and if not available, periodical comparison 
with patient samples should be utilized.
Key words: CRP; POCT; inter-lot variation; primary 
health care; general practitioner
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in the public bid for glucose strips for 
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Background: The need for ease and rapidness of 
laboratory sample testing depends on the pa-
tient’s particular clinical situation, localization and 
available therapeutic strategies. In the context of a 
public bid for glucose reactive strips, the Depart-
ment of Clinical Analysis participated in the techni-
cal evaluation of the commercial pont-of-care sys-
tems, together with the Department of Endo-
crinology and the Department of Management. 
Materials and methods: Given the three compet-
ing kits (Abbott XceedPro®, Menarini StatStrip®, Ro-
che Accu-Chek Aviva®), we evaluated each of the 
following characteristics: type of sample, sample 
volume, range of linearity, correction for haemat-
ocrit, duration of analysis, connectivity, informa-
tion accessibility, user online teaching, data man-
agement software, traceability and price. The final 
decision relied on a common agreement among 
the three departments, giving higher considera-
tion to price, information accessibility and data 
management.
Results: All three commercial strips used similar 
sample volumes and ranges of linearity, whereas 
the duration of analysis varied considerably, being 
shortest for Roche’s. Menarini presented more in-
formative data management software, thus allow-
ing a better assessment of hospital glucose levels. 
On the other hand, Roche’s offer included tester 
wireless connection, remote actualizations, user e-
learning and total result traceability. 
Conclusions: The implantation of point-of-care 
systems for glucose testing in hospitals represents 
a great opportunity for laboratory professionals to 
contribute in the organization, management and 
accreditation of these processes and therefore 
warrantee higher patient safety.
Active participation of such specialists in both 
drafting and evaluation of public bids for point-of-
care testing is crucial in order to maximize cost-ef-
fectiveness and yield traceable results.
Key words: glucose strips; traceability; data man-
agement
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Background: The Laboratory Director plays a de-
cisive role in the governance of all POCT aspects. 
In particular: definition of technical specifications, 
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management of errors, implementation and moni-
toring of quality control procedures. QIs can be an 
efficient quality assurance tool to be used. Aim of 
this work is to describe the flow chart and the QIs 
results (2009-2013) collected in our Department.
Materials and methods: Five QIs have been de-
fined concerning instruments maintenance and 
performances obtained in internal quality control 
(IQC). Yearly data have been compared from 91 
POCT: 54 Glucose meters and 37 Blood gas analyz-
ers.
Results: Glucose meters. The number of unaccept-
able performances obtained in IQC is significantly 
decreased, from 8.6% (2009) to 1.5% (2013). The 
number of suboptimal values of coefficient of vari-
ation percentage is decreased from 1.6% (2010), 
for either concentration levels, to 0.3% and 0% 
(2013), for level 1 and level 2, respectively. The per-
centage of incorrect identification of IQC lots or 
reagent strips is decreased from 5.2% (2011) to 
0.4% (2013). Blood gas analyzer: the number of de-
layed maintenance or electrodes replacement is 
constant over time (3.68%).
Conclusion: The results demonstrated that the 
continuous monitoring of POCT performances, us-
ing QIs, is a useful tool to check and improve the 
procedures used by the operators that work out-
side the laboratory walls. The quality governance 
by the laboratory is a critical prerequisite to im-
prove the activities of POCT and the use of QIs 
helps the laboratory staff to monitor the proce-
dures, identify the errors and know the need of 
the preventive/corrective actions.
Key words: point-of-care-testing; quality indica-
tors; quality assurance
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Background: Self-monitoring of blood glucose 
(SMBG) is considered an important component of 
diabetic patient management; recently there have 
been arguments whether all patients should use 
SMBG, especially type 2 diabetics (T2Ds) not on in-
sulin. Most of the studies have conclusions that 
use of SMBG for T2Ds may not be beneficial and 
must be weighed against the expense and incon-
venience. The aim of this study was to determine 
the glycemic control status of T2Ds using SMBG 
who are admitted to our endocrinology clinic.
Materials and methods: The questionnaires were 
filled by diabetic patients admitted to our Endo-
crinology Clinic between the 28th June 2013 and 
30th July 2013. The diabetes care quality biomark-
ers such as HbA1c, lipids (HDL-Chol, LDL-Chol, trig-
lycerides) were measured.
Results: The number of patients whose HbA1c can 
be measured was 47 [ages: mean (SD): 53.9 (11.3), 
diabetes duration: 8.7 (6.6)]. 80.9% (N = 38) are 
T2Ds and 68.1% (N = 32) are using insulin. 57.4% (N 
= 27), 31.9% (N = 15), and 10.6% (N = 5) patients 
were found as obese, overweight and normal, re-
spectively. 97.9% (N = 46) have glucose meters; but 
74.5% (N = 35) and 93.6% (N = 44) don’t know 
about accuracy control and calibration, respective-
ly. The percentages of patients that are out of the 
targets recommended by the ADA were found as 
48.9% (N = 23), 35% (N = 6), 61% (N = 17), 40.4% (N 
= 19), 40.4% (N = 19) for HbA1c, HDL-C for males, 
HDL-C for females, LDL-C and TG, respectively. The 
previous glucose values obtained from glucose 
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meters didn’t show good correlation with HbA1c 
values (r = 0.39, P = 0.02).
Conclusion: Although this study has limited 
number of patients, it may be concluded that the 
SMBG is limited clinical effectiveness in improving 
glycemic control.
Key words: self monitoring blood glucose; clinical 
effectiveness
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Background: Dyslipidemia has been described in 
treated HIV-patients as a side effect of antiretrovi-
ral therapy and therefore lipid status is an essential 
part of monitoring HIV-positive patients. In the 
present study we compared measured with calcu-
lated low density lipoprotein cholesterol (LDL-C) 
(Friedewald’s formula and a recently new 
Anandaraja’s formula) in HIV-positive patients.
Materials and methods: Determination of triglyc-
erides and cholesterol (Thermo Fisher Scientific, 
USA), direct LDL-C (D-LDL-C) and HDL-C (Dijagnos-
tika d.o.o., Croatia) was done on Beckman Coulter 
AU400 analyzer in sera of HIV-positive patients (N 
= 98). Calculation of LDL-C with Friedewald’s and 
Anandaraja’s formulas was performed. Measured 
D-LDL-C was compared with calculated LDL-C. Sta-
tistical analysis was done with MedCalc software 
(version 12.7.0).
Results: Mean and standard deviation for LDL-C 
concentrations were as follows: 2.53 ± 0.79 mmol/L 
(D-LDL-C), 3.15 ± 1.13 mmol/L calculated by Friede-
wald’s formula (F-LDL-C) and 3.46 ± 1.14 mmol/L 
calculated by Anandaraja’s formula (A-LDL-C). 
Passing-Bablok regression analysis showed a con-
stant difference between D-LDL-C and F-LDL-C, 
but not between D-LDL-C and A-LDL-C and a pro-
portional difference for measured D-LDL-C and 
both equations (D-LDL-C vs. F-LDL-C: y=-0.259 + 
1.353 x; D-LDL-C vs. A-LDL-C: y = -0.425 + 1.500 x). 
Bland-Altman plot showed a mean difference be-
tween methods: D-LDL-C vs. F-LDL-C -0.62 mmol/L 
(95% CI: -1.50 to 0.27) and D-LDL-C vs. A-LDL-C 
-0.93 mmol/L (95% CI: -2.07 to 0.21).
Conclusion: According to our results, measured 
and calculated LDL-C should not be used inter-
changeably in HIV-postive patients. Friedewald’s 
and Anandaraja’s equation generally overestimate 
LDL-C in HIV patients.
Key words: low density lipoprotein cholesterol; 
Friedewald’s formula; Anandaraja’s formula
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How well are patients with diabetes 
mellitus educated to measure glucose 
levels at home using a glucometer?
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Background: Daily monitoring of glucose levels in 
patients with diabetes mellitus is performed by di-
abetic patients themselves using a glucometer at 
home. For accurate results of measurements, it is 
paramount that patients are educated on the cor-
rect preparation and methods of using a glucom-
eter.
Aim: To examine how well patients with diabetes 
mellitus are educated regarding the correct meth-
ods for accurate glucose measurements using a 
glucometer at home.
Materials and methods: An anonymous ques-
tionnaire was given to patients who were diag-
nosed with diabetes mellitus and were also re-
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ferred for blood tests at the Medical Biochemistry 
Laboratory of Health Institution Varaždin County. 
The questionnaire was filled by 76 patients, with 
an average age of 61, ranging between ages 25-93 
years and of which 50% were women. The ques-
tionnaire contained 14 questions about their treat-
ment, the method of obtaining instructions, clarity 
of received instructions, the preparation of pa-
tients and the measurement of glucose.
Results: In the observed group, 86% of the pa-
tients use glucometers at home. Of these, 85% of 
them obtained a glucometer and 15% bought one. 
The patients received a glucometer mostly from 
doctors (67%) and pharmacists (14%). Instructions 
about the method of glucose level measurements 
were mostly given by doctors (66%) and nurses 
(22%). Those instructions were clear to 97% of pa-
tients. Instructions about the use and calibration 
obtained with the device were read by 91% of pa-
tients. The majority of patients measure glucose 
once a day (37%), 19% measure it twice a day and 
23% measure it three times a day. 45% of patients 
measure glucose levels before their meal, 23% of 
patients measure glucose levels after their meal 
while 32% of them measure it before and after 
their meal. 82% of patients who measure glucose 
levels after their meal, measure it exactly two 
hours after.
Conclusion: Patients are well informed about the 
measurement of glucose levels using a glucometer 
at home and subsequently perform the measure-
ments mostly in the correct way. However, a larger 
number of Diabetic patients should be involved in 
monitoring of glucose levels by using glucometer 
at home.
Key words: diabetes mellitus; glucometer; meas-
urement
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Background: Our hospital conducts programs of 
comprehensive management of cancer diseases in 
terms of prevention, early detection, diagnostics 
and treatment. We follow all professional and tech-
nical requirements laid down by the Rule on medi-
cal laboratories in Slovenia (2004), which stipulates 
particular requirements for ensuring competent 
and high quality POCT.
Materials and methods: POCT analyses are car-
ried out on 18 glucose POCT devices in different 
hospital units and on two blood gas analyzers in 
the Intensive Care Unit, where blood gas, pH, elec-
trolytes, metabolites and haemoglobin are tested. 
All glucometers in our hospital are made by the 
same manufacturer (Hemocue), which helps to en-
sure a uniformity of patient results. Since June 
2010 an analysis of two control samples, which are 
prepared in the laboratory, has been performed 
on all glucometers. During each control cycle, the 
results are statistically evaluated and compared 
within the group of glucometers. From this year 
on we are also participating in an international ex-
ternal control scheme for POCT. Blood gas analysis 
is performed on two Rapidlab 1265 (Siemens). 
Analysis and everyday maintenance of the analyz-
ers is performed by hospital nurses. More complex 
maintenance of the analyzers and an evaluation of 
the internal quality control results are performed 
by our laboratory. For both blood gas analyzers, 
the internal quality control samples are taken by 
using the Automatic Quality Control Cartridges 
three times a day, and the international external 
quality control samples are taken once a month.
Our ambition for the future is to introduce identifi-
cation codes for POCT operators and patients’ 
samples and to ensure a transfer of POCT results 
into the hospital information system.
Key words: POCT; legal basis; quality control
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Background: The aim of this study was to compa-
re haemoglobin and haematocrit levels measured 
as point of care testing and measurements done 
by automated haematology analyzer.
Materials and methods: In this prospective study, 
haemoglobin and haematocrit levels were meas-
ured in 126 consecutive paired arterial or capillary 
samples using a point of care blood gas analyzer 
and automated haematology analyzer. Pearson 
correlation coefficient and Passing-Bablok regres-
sion were calculated for the data comparison.
Results: Mean (SD) level of haemoglobin meas-
ured on blood gas analyzer was 135.59 g/L (26.48) 
and measured on automated haematology ana-
lyzer 118.84 g/L (25.59). The mean difference be-
tween the blood gas analyzer and automated hae-
matology analyzer was -16.75 g/L (P  <  0.001). 
Mean (SD) level of haematocrit measured on blood 
gas analyzer was 0.399 L/L (0.078) and measured 
on automated haematology analyzer 0.356 L/L 
(0.071), respectively. The mean difference between 
the blood gas analyzer and automated haematol-
ogy analyzer was -0.043 L/L (P  <  0.001). Compari-
son of the results of two devices yielded correla-
tion coefficients r = 0.98 (P < 0.001) for haemo-
globin and r = 0.75 (P < 0.001) for haematocrit.
Conclusions: Although the correlations between 
the measurements were significant, blood gas an-
alyzer has shown unacceptable agreement with 
automated haematology analyzer. It overestimates 
haemoglobin and haematocrit values, which is not 
clinically acceptable.
Key words: point–of-care; blood gas analyzer; 
haematology analyzer; haemoglobin; haematocrit
